Metabolic therapy for ischemic heart disease: The rationale for inhibition of fatty acid oxidation

Heart Failure Reviews

Volumn 10, Issue 4, 2005, Pages 275-279

  Stanley, William C ^a,b   Sabbah, Hani N ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACETYL COENZYME A; ACETYL COENZYME A ACETYLTRANSFERASE; ADENOSINE TRIPHOSPHATE; CARBOHYDRATE; CARNITINE PALMITOYLTRANSFERASE; FATTY ACID; LACTIC ACID; OXYGEN; PYRUVATE DEHYDROGENASE; PYRUVIC ACID; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; TRIMETAZIDINE;

ACIDOSIS; ARTICLE; BIOACCUMULATION; CARBOHYDRATE METABOLISM; CELL PH; DRUG MECHANISM; ENERGY; FATTY ACID OXIDATION; GLYCOLYSIS; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HUMAN; ISCHEMIC HEART DISEASE; OXYGEN CONSUMPTION;

CARBOHYDRATE METABOLISM; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; ENERGY METABOLISM; FATTY ACIDS; HUMANS; MYOCARDIAL ISCHEMIA; OXIDATION-REDUCTION; TRIMETAZIDINE; VASODILATOR AGENTS;

EID: 33645468614     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10741-005-7542-4     Document Type: Article

References (37)

1. Stanley WC, Lopaschuk GD, Hall JL, et al., Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions. Cardiovasc Res 1997;33:243-257.
2. Fox KM, Mulcahy D, Findlay I, et al., The Total Ischaemic Burden European Trial (TIBET). Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. The TIBET Study Group. Eur Heart J 1996;17:96-103.
3. Akhras F, Jackson G. Efficacy of nifedipine and isosorbide mononitrate in combination with atenolol in stable angina. Lancet 1991;338:1036-1039.
4. Savonitto S, Ardissiono D, Egstrup K, et al., Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris. Results of the International Multicenter Angina Exercise (IMAGE) Study. J Am Coll Cardiol 1996;27:311-316.
5. Packer M. Drug therapy. Combined beta-adrenergic and calcium-entry blockade in angina pectoris. N Engl J Med 1989;320:709-718.
6. Chandler MP, Chavez PN, McElfresh TA, et al., Partial inhibition of fatty acid oxidation increases regional contractile power and efficiency during demand-induced ischemia. Cardiovasc Res 2003;59:143-151.
7. Dyck JR, Cheng JF, Stanley WC, et al., Malonyl coenzyme a decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation. Circ Res 2004;94:e78-e84.
8. Stanley WC, Morgan EE, Huang H, et al., Malonyl-CoA decarboxylase inhibition suppresses fatty acid oxidation and reduces lactate production during demand-induced ischemia. Am J Physiol Heart Circ Physiol 2005;289:H2304-H2309.
9. Kennedy JA, Horowitz JD. Effect of trimetazidine on carnitine palmitoyltransferase-1 in the rat heart. Cardiovasc Drugs Ther 1998;12:359-363.
10. Stanley WC. Partial fatty acid oxidation inhibitors for stable angina. Expert Opin Investig Drugs 2002;11:615-629.
11. Kantor PFLGDOLH. Myocardial energy metabolism. In: Opie LH, editor. Heart Physiology and Pathophysiology, Academic Press, 2004: 543-569.
12. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005;85:1093-1129.
13. Balaban RS, Kantor HL, Katz LA, et al., Relation between work and phosphate metabolite in the in vivo paced mammalian heart. Science 1986;232:1121-1123.
14. Sharma N, Okere IC, Brunengraber DZ, et al., Regulation of pyruvate dehydrogenase activity and citric acid cycle intermediates during high cardiac power generation. J Physiol 2005;562:593-603.
15. Wisneski JA, Stanley WC, Neese RA, et al., Effects of acute hyperglycemia on myocardial glycolytic activity in humans. J Clin Invest 1990;85:1648-1656.
16. Stone CK, Holden JE, Stanley W, et al., Effect of nicotinic acid on exogenous myocardial glucose utilization. J Nucl Med 1995;36:996-1002.
17. Lassers BW, Wahlqvist ML, Kaijser L, et al., Effect of nicotinic acid on myocardial metabolism in man at rest and during exercise. J Appl Physiol 1972;33:72-80.
18. Kurien VA, Oliver MF. Serum-free-fatty-acids after acute myocardial infarction and cerebral vascular occlusion. Lancet 1966;2:122-127.
19. Lopaschuk GD, Belke DD, Gamble J, et al., Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim Biophys Acta 1994;1213:263- 276.
20. Bing RJ. The metabolism of the heart. Harvey Lect 1955;50:27-70.
21. Randle PJ, Newsholme EA, Garland PB. Regulation of glucose uptake by muscle. 8. Effects of fatty acids, ketone bodies and pyruvate, and of alloxan-diabetes and starvation, on the uptake and metabolic fate of glucose in rat heart and diaphragm muscles. Biochem J 1964;93:652-665.
22. Higgins AJ, Morville M, Burges RA, et al., Oxfenicine diverts rat muscle metabolism from fatty acid to carbohydrate oxidation and protects the ischaemic rat heart. Life Sci 1980;27:963-970.
23. Higgins AJ, Morville M, Burges RA, et al., Mechanism of action of oxfenicine on muscle metabolism. Biochem Biophys Res Commun 1981;100:291-296.
24. Kerbey AL, Radcliffe PM, Randle PJ. Diabetes and the control of pyruvate dehydrogenase in rat heart mitochondria by concentration ratios of adenosine triphosphate/ adenosine diphosphate, of reduced/oxidized nicotinamide-adenine dinucleotide and of acetyl-coenzyme A/coenzyme A. Biochem J 1977;164:509-519.
25. Gertz EW, Wisneski JA, Neese R, et al., Myocardial lactate extraction: multi-determined metabolic function. Circulation 1980;61:256-261.
26. Wisneski JA, Gertz EW, Neese RA, et al., Metabolic fate of extracted glucose in normal human myocardium. J Clin Invest 1985;76:1819-1827.
27. El Banani H, Bernard M, Baetz D, et al., Changes in intracellular sodium and pH during ischaemia-reperfusion are attenuated by trimetazidine. Comparison between low- and zero-flow ischaemia. Cardiovasc Res 2000;47:688- 696.
28. Fabiato A, Fabiato F. Effects of pH on the myofilaments and the sarcoplasmic reticulum of skinned cells from cardiace and skeletal muscles. J Physiol 1978;276:233-255.
29. Liedtke AJ. Alterations of carbohydrate and lipid metabolism in the acutely ischemic heart. Prog Cardiovasc Dis 1981;23:321-336.
30. McNulty PH, Sinusas AJ, Shi CQ, et al., Glucose metabolism distal to a critical coronary stenosis in a canine model of low-flow myocardial ischemia. J Clin Invest 1996;98:62-69.
31. Panchal AR, Comte B, Huang H, et al., Acute hibernation decreases myocardial pyruvate carboxylation and citrate release. Am J Physiol Heart Circ Physiol 2001;281:H1613-H1620.
32. Lei B, Matsuo K, Labinskyy V, et al., Exogenous nitric oxide reduces glucose transporters translocation and lactate production in ischemic myocardium in vivo. Proc Natl Acad Sci U S A. 2005;102:6966-6971.
33. Opie LH. The Heart: Physiology and Metabolism. New York, Raven Press, 1991.
34. Stanley WC, Marzilli M. Metabolic therapy in the treatment of ischaemic heart disease: The pharmacology of trimetazidine. Fundam Clin Pharmacol 2003;17:133- 145.
35. Kantor PF, Lucien A, Kozak R, et al., The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000;86:580-588.
36. Kennedy JA, Kiosoglous AJ, Murphy GA, et al., Effect of perhexiline and oxfenicine on myocardial function and metabolism during low-flow ischemia/reperfusion in the isolated rat heart. J Cardiovasc Pharmacol 2000;36:794-801.
37. Wolff AA, Rotmensch HH, Stanley WC, et al., Metabolic approaches to the treatment of ischemic heart disease: The clinicians' perspective. Heart Fail Rev 2002;7:187-203.